Royston Glasspool
Direktor/Vorstandsmitglied bei RELMADA THERAPEUTICS, INC.
Vermögen: - $ am 30.04.2024
Profil
Royston John Glasspool is currently serving as a Director at the Biotechnology Innovation Organization.
He is also an Independent Director at Relmada Therapeutics, Inc., DalCor Pharmaceuticals Canada, Inc., and a Venture Partner at Agent Capital LLC.
Previously, Glasspool held the position of Chief Executive Officer & Director at Anthos Therapeutics, Inc. from 2019 to 2024.
He also served as Director & Vice President at European Vaccine Manufacturers from 2010 to 2012, VP-Emerging Therapies & Market Development at Baxter International, Inc. from 2012 to 2015, and EVP, Head-Corporate Strategy & Customer Operations at Baxalta, Inc. from 2015 to 2017.
Glasspool was also the Head-Europe Region, Vaccines & Diagnostics at Novartis AG from 2009 to 2012.
In terms of education, Glasspool completed his undergraduate studies at Oxford Brookes University and Staffordshire University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
RELMADA THERAPEUTICS INC
-.--% | 27.03.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Royston Glasspool
| Unternehmen | Position | Beginn |
|---|---|---|
| RELMADA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 19.12.2019 |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Direktor/Vorstandsmitglied | - |
DalCor Pharmaceuticals Canada, Inc.
 DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | Direktor/Vorstandsmitglied | 01.05.2017 |
Agent Capital LLC
 Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts. | Private Equity Investor | 01.01.2018 |
Ehemalige bekannte Positionen von Royston Glasspool
| Unternehmen | Position | Ende |
|---|---|---|
Anthos Therapeutics, Inc.
 Anthos Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Anthos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops and commercializes innovative therapies for high-risk cardiovascular patients. It offers MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway. The company was founded by Paris Panayiotopoulos, Ari Brettman and Jonathan E. Freeman in 2018 and is headquartered in Cambridge, MA. | Vorstandsvorsitzender | 22.04.2024 |
| BAXALTA INC | Corporate Officer/Principal | 01.01.2017 |
| BAXTER INTERNATIONAL INC. | Corporate Officer/Principal | 01.06.2015 |
| European Vaccine Manufacturers | Direktor/Vorstandsmitglied | 01.12.2012 |
| NOVARTIS AG | Corporate Officer/Principal | 01.08.2012 |
Ausbildung von Royston Glasspool
| Oxford Brookes University | Undergraduate Degree |
| Staffordshire University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| RELMADA THERAPEUTICS, INC. | Health Technology |
| NOVARTIS AG | Health Technology |
| BAXTER INTERNATIONAL INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | Health Technology |
Anthos Therapeutics, Inc.
Anthos Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Anthos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops and commercializes innovative therapies for high-risk cardiovascular patients. It offers MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway. The company was founded by Paris Panayiotopoulos, Ari Brettman and Jonathan E. Freeman in 2018 and is headquartered in Cambridge, MA. | Health Technology |
Baxalta, Inc.
 Baxalta, Inc. BiotechnologyHealth Technology Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL. | Health Technology |
| European Vaccine Manufacturers | |
Agent Capital LLC
Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts. | Finance |
